Related Experiment Video
Updated: Mar 2, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Continuous Subcutaneous Insulin Infusion in Children: A Pilot Study Validating a Protocol to Avoid Hypoglycemia at
Despoina Manousaki1,2, Johnny Deladoëy1,2, Louis Geoffroy1,2
1Endocrinology Service and Diabetes Unit, CHU Sainte-Justine, Montreal, QC, Canada.
Insights
This study shows that a new protocol for starting continuous subcutaneous insulin infusion (CSII) is safe for children with type 1 diabetes. The CSII initiation protocol effectively prevents hypoglycemia in pediatric patients.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Systematic studies on hypoglycemia and hyperglycemia during continuous subcutaneous insulin infusion (CSII) initiation in children with type 1 diabetes are lacking.
- Assessing the safety of CSII initiation protocols is crucial for pediatric diabetes care.
Purpose of the Study:
- To evaluate the safety of a specific CSII initiation protocol in pediatric patients with type 1 diabetes.
- To determine the impact of CSII initiation on glycemic control, specifically hypoglycemia and hyperglycemia, in children.
Main Methods:
- Prospective study involving 22 pediatric patients with type 1 diabetes.
- Continuous glucose monitoring (CGM) was used to assess glycemic values before and within 3 days after CSII initiation.
Main Results:
- No significant difference was observed in the rates of hypoglycemic events (RR = 0.85, p = 0.52) or prolonged hypoglycemic events (>1 h) per day (RR = 1.12, p = 0.56) after CSII initiation.
- A trend towards prolonged hyperglycemia episodes was noted post-pump initiation (RR = 1.52, p = 0.06).
Conclusions:
- This prospective study is the first to utilize CGM to assess the impact of a CSII initiation protocol on glycemic control in children.
- The established CSII initiation protocol demonstrates a safe model for avoiding hypoglycemia in pediatric patients starting insulin pump therapy.
Background:
The occurrence of hypoglycemia and hyperglycemia during the first days after transition to continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes has not been systematically studied in children. The aim of this prospective study was to demonstrate that the protocol applied in our diabetes clinic is safe at CSII initiation in children.
Methods:
We assessed 22 pediatric patients with type 1 diabetes, using continuous glucose monitoring (CGM) before and after CSII initiation (±3 days).
Results:
After CSII initiation, there was no difference in the rates of hypoglycemic events expressed as relative rates (RRs) per person-reading (RR = 0.85, p = 0.52, 95% CI 0.52-1.39), as well as in the number of prolonged hypoglycemic events (>1 h) per day (RR = 1.12, p = 0.56, 95% CI 0.75-1.68). We observed only a trend toward prolonged episodes of hyperglycemia after pump initiation (RR = 1.52, p = 0.06, 95% CI 0.97-2.35).
Conclusion:
Our study is the first to assess, through CGM and in a prospective way, the impact of a CSII initiation protocol on glycemic values. Our protocol provides a safe model to avoid hypoglycemia at CSII initiation in children.
Clinical Trial Registration:
www.ClinicalTrials.gov, identifier NCT01840358.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Drug Dosing: Infants and Children
Hypoglycemia and Glucagon
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
IV Infusion to Oral Dosing: Conversion Methods

